Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,772 across all filing types
Latest filing 2025-11-17 Transaction in Own Shar…
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Release of a capital market information
Transaction in Own Shares Classification · 1% confidence The document is an official announcement from Evotec SE regarding the completion of a share repurchase programme. It details the number of shares acquired, the volume-weighted average price, and the total transaction amount over a specific period. This falls directly under the definition of 'Transaction in Own Shares' (POS), which covers reports of a company buying back its own shares.
2025-11-17 English
Evotec SE: Dr. Cord Dohrmann, sell
Director's Dealing Classification · 1% confidence The document is a formal notification of a transaction by a person discharging managerial responsibilities (Dr. Cord Dohrmann, a member of the managing body of Evotec SE). It explicitly details the nature of the transaction (disposal of shares), the price, volume, date, and the identification of the issuer. This aligns perfectly with the definition of a Director's Dealing (DIRS) filing.
2025-11-14 English
Evotec SE: Wesley Wheeler, buy
Director's Dealing Classification · 1% confidence The document is a formal notification of a transaction by a person discharging managerial responsibilities (PDMR), specifically Wesley Wheeler, a member of the administrative or supervisory body of Evotec SE. It details the nature of the transaction (acquisition of shares), the price, volume, and date. This aligns perfectly with the definition of a Director's Dealing (DIRS) filing.
2025-11-13 English
Evotec receives milestone payment from Bristol Myers Squibb following IND acceptance in strategic protein degradation partnership
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing a milestone payment received by Evotec SE from Bristol Myers Squibb following an IND acceptance. It follows the standard format of a corporate news announcement disseminated via a regulatory news service (EQS). Since it does not fit into specific categories like earnings releases, financial reports, or governance filings, and is a general corporate announcement, it is classified as a Regulatory Filing (RNS).
2025-11-12 English
Release of a capital market information
Transaction in Own Shares Classification · 1% confidence The document is an official announcement by Evotec SE regarding the implementation of a share repurchase program. It explicitly references Article 5(1)(a) of Regulation (EU) No. 596/2014, which governs share buybacks. Since the document details the company's intent to buy back its own shares, it falls under the category of 'Transaction in Own Shares' (POS).
2025-11-06 English
Q3 statement / Q3 financial report 2025
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report covering the first nine months (9M) of 2025. It includes detailed consolidated income statements, segment information (D&PD and JEB), and a 'Report on the Financial Situation and Results' section. It provides actual financial data, analysis of business trends, and performance metrics, which distinguishes it from a mere earnings release or a report publication announcement. Therefore, it is classified as an Interim/Quarterly Report. 9M 2025
2025-11-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.